• Eikon posted a full-year net loss attributable to common stockholders of $334 million, widening from $244 million.
• Operating loss expanded to $339 million as research and development expense climbed 22% to $250 million.
• General and administrative costs jumped 59% to $89 million, driven mainly by a $21 million impairment tied to vacated properties.
• Cash, cash equivalents, and marketable securities totaled $336 million at year-end; an upsized IPO in February raised $381 million in gross proceeds.
• Completed enrollment in TeLuRide-005 Phase 2 trial of EIK1001 in first-line stage 4 non-small cell lung cancer, with a comprehensive data set expected in 2H 2026; cash runway forecast into 2H 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eikon Therapeutics Inc. published the original content used to generate this news brief on March 30, 2026, and is solely responsible for the information contained therein.